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Abstract  
 
Aim: To assess the clinical relevance of transgenic and patient-derived xenograft models of 
adamantinomatous craniopharyngioma (ACP) using serial magnetic resonance imaging (MRI) and 
high resolution post-mortem micro-computed tomography (μ-CT), with correlation with histology 
and human ACP imaging. 
Methods: The growth patterns and radiological features of tumours arising in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ transgenic mice, and of patient-derived ACP xenografts implanted in the 
cerebral cortex, were monitored longitudinally in vivo with anatomical and functional MRI, and by 
ex vivo μ-CT at study end. Pathological correlates with haematoxylin and eosin stained sections 
were investigated. 
Results: Early enlargement and heterogeneity of Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse pituitaries was 
evident at initial imaging at 8 weeks, which was followed by enlargement of a solid tumour, and 
development of cysts and haemorrhage. Tumours demonstrated MRI features that recapitulated 
those of human ACP, specifically, T1-weighted signal enhancement in the solid tumour component 
following Gd-DTPA administration, and in some animals, hyperintense cysts on FLAIR and T1-
weighted images. Ex vivo μ-CT correlated with MRI findings and identified smaller cysts, which 
were confirmed by histology. Characteristic histological features, including wet keratin and 
calcification, were visible on μ-CT and verified by histological sections of patient-derived ACP 
xenografts. 
Conclusions: The Hesx1Cre/+;Ctnnb1lox(ex3)/+ transgenic mouse model and cerebral patient-derived 
ACP xenografts recapitulate a number of the key radiological features of the human disease and 
provide promising foundations for in vivo trials of novel therapeutics for the treatment of these 
tumours. 
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Introduction 
 
Adamantinomatous craniopharyngioma (ACP) is the most common tumour of the sellar region in 
childhood, accounting for approximately 1.2-4% of paediatric intracranial tumours. Peak incidence 
occurs at 5-9 years with a second peak in adults aged 45-60 years (20, 21). Although appearing 
histopathologically benign and classified by the World Health Organisation as grade I (17), ACP is 
often clinically aggressive, demonstrating invasion of the hypothalamus and visual pathways, and 
destruction of the pituitary. Current treatment strategies involve surgery, radiotherapy and cystic 
drainage. Although associated with good 5 year survival, patients frequently suffer severe long term 
morbidity, with pituitary and hypothalamic dysfunction, visual impairment and poor quality of life 
(20).  
 
ACP is an epithelial lesion thought to arise from Rathke’s pouch, the embryonic primordium of the 
anterior pituitary, and is characterised by the formation of a peripheral basal layer of palisading 
epithelium, loose aggregates of stellate cells, nodules of “wet keratin” (anuclear ‘ghost cells’), 
whorl-like cell clusters and cysts containing high levels of protein, cholesterol and calcification 
(19). ACPs present as variably cystic/solid tumours in the intrasellar and/or suprasellar region by 
both magnetic resonance imaging (MRI) and computed tomography (CT) (10). Calcification, 
present in over 90% of ACPs, is detectable by CT, which is therefore widely used for differential 
diagnosis following initial identification by MRI (29).  
 
Mutations in CTNNB1, which encodes β-catenin, predicted to cause the over-activation of the WNT 
pathway, have been identified in the majority of human ACP samples analysed (7, 9, 15, 24). 
Unusually, nuclear-cytoplasmic localisation of activated β-catenin is found in only a small 
proportion of tumour cells, either as small cell clusters, which broadly correlate with epithelial 
whorls, or otherwise dispersed in a minority of cells throughout the tumour (9, 11). We have 
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recently described the 3D structure of human ACP using high resolution micro-CT (µ-CT) imaging 
(2), and corroborated the presence of clusters at the leading invasive edge of tissue invasion (8, 26).  
 
Expression of oncogenic β-catenin in the developing pituitary in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice 
results in tumours resembling human ACP at the histological and molecular levels (11). Despite 
activation of β-catenin in all pituitary cells in this model, nuclear accumulation is only observed in 
small clusters of cells, analogous to human clusters. Previous studies have shown that these mice 
have a median survival of approximately 11 weeks, with a remarkable variability, and at the time of 
death exhibit large cystic masses beneath the brain (11). To date, the kinetics of tumour 
development in this transgenic mouse model of ACP has not been studied. 
 
A patient-derived xenograft model of ACP has also been established through placement of 
uncultivated human tumour tissue into the cerebral hemisphere of immunodeficient mice (26). 
Lesions propagated in this manner show comparable tissue architecture and express similar 
immunohistochemical markers to the patient tumours, including whorl-like cell clusters with 
nuclear β-catenin accumulation and activated EGFR (26). 
 
In this study we have further characterised tumours arising in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
transgenic mouse model of ACP in vivo, describing both their radiological features and patterns of 
growth through longitudinal multiparametric MRI imaging. Using μ-CT we have assessed both 
these murine tumours, and cerebral patient-derived ACP xenografts, ex-vivo in 3D at high 
resolution. Comparison with clinical imaging and pathology demonstrated that both these models 
recapitulate the radiological features of human ACP. 
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Materials and Methods 
 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ transgenic model of ACP 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice have been described previously (11). All experiments were 
performed in accordance with the local Animal Welfare and Ethical Review Board, the UK Home 
Office Animals (Scientific Procedures) Act 1986, the United Kingdom National Cancer Research 
Institute guidelines for the welfare of animals in cancer research (30) and the ARRIVE (animal 
research: reporting in vivo experiments) guidelines (16). Eighteen Hesx1Cre/+;Ctnnb1lox(ex3)/+ and 
four wildtype control mice were assessed in this study. 
 
Patient-derived ACP xenograft model 
A fresh surgical specimen from a 56 year old male patient with ACP was retrieved from the 
Department of Neurosurgery at the University Hospital Erlangen. Tumour tissue was verified and 
classified as previously and was found to bear a TCT(Ser)>TGT(Cys) mutation in codon 33 of 
CTNNB1 but no mutation in exon 15 of BRAF (13, 26). A declaration of consent for the patient is 
available, approved by the local ethics committee of the Friedrich-Alexander-Universität Erlangen-
Nürnberg. Procedures were conducted in accordance to the Declaration of Helsinki. 
All experiments performed were authorised by the local government (Regierung von Unterfranken, 
Germany, Ref.-No. 54-2532.01-25/14) in accordance with the animal protection act. The surgical 
specimen was divided and implanted into the right cerebral hemisphere of four female NMRI-
Fox1nu/Fox1nu mice (Janvier Labs, Le Genest-Saint-Isle, France). Anaesthetised mice were secured 
in a stereotactic frame (Bilaney Consultants, Düsseldorf, Germany), a 5mm incision made in the 
scalp and a 1mm burr hole drilled 3mm lateral to the bregma. A piece of uncultivated tumor tissue 
(1–8mm3) was inserted through the hole using a sterile cannula and the skin closed using a suture 
(ETHILON*II 4-0, Ethicon, Norderstedt, Germany). Analgesic (1mg/g metamizole, Ratiopharm, 
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Ulm, Germany) was added to the drinking water for 3 days following the procedure.  Body weight 
and animal behaviour were monitored daily (26). 
 
Magnetic resonance imaging  
1H MRI of Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice was performed on a 7T horizontal bore microimaging 
system (Bruker, Ettlingen, Germany) using a 30mm birdcage coil and 1mm thick slices acquired 
over a 25mm x 25mm field of view (FOV). Imaging was performed fortnightly from approximately 
8 weeks of age, increasing to weekly once tumour progression was established. Anaesthesia was 
induced with either 3% isoflurane in 100% oxygen (1L/min) and maintained with 1% isoflurane 
(for longitudinal screening/monitoring), or a 10ml/kg intraperitoneal injection of fentanyl citrate 
(0.315mg/ml) plus fluanisone (10mg/ml (Hypnorm; Janssen Pharmaceutical Ltd. High Wycombe, 
UK)), midazolam (5mg/ml (Hypnovel; Roche, Burgess Hill, UK)), and sterile water (1:1:2) (for 
functional MRI at study end). A lateral tail vein was cannulated with a 27G butterfly catheter 
(Venisystems, Hospira, Royal Leamington Spa, UK) if remote administration of Gd-DTPA 
(Magnevist™; Schering, Berlin, Germany) was required. Core body temperature was maintained by 
warm air blown through the magnet bore. 
Magnetic field homogeneity was first optimised by shimming over the entire brain using an 
automated shimming routine (FASTMAP). Anatomical multi-slice contiguous T2-weighted RARE 
images (TR=4500ms, TEeff=36ms, 8 averages, 256x256 matrix, pixel size=98µmx98µm) were then 
acquired to monitor tumour development and for subsequent volumetric analysis. Fluid attenuated 
inversion recovery (FLAIR; TR=18000ms, TEeff=35ms, TI=2100ms, 4 averages, flip angle=125°, 
128x128 matrix) and T1-weighted (TR=1300ms, TE=7.5ms, 4 averages, RARE factor=8, 256x256 
matrix) images were also acquired. At study end, echo-planar diffusion-weighted imaging (EPI-
DWI) was used to determine the apparent diffusion coefficient (ADC) (5), and either T1-weighted 
images acquired before and 1 minute after intravenous administration of 0.1mmolkg-1 Gd-DTPA 
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(Magnevist, Schering), or dynamic contrast-enhanced (DCE) MRI (4) was used to assess patent 
tumour vasculature. 
MRI of nude mice bearing cerebral patient-derived ACP xenografts was performed between 124 
and 130 days after tumour implantation, at which time successful tumour engraftment had  
previously been confirmed histologically (26), under isoflurane anaesthesia, on a 7T horizontal bore 
microimaging system (Bruker, Ettlingen, Germany) equipped with a dedicated mouse brain coil and 
an animal monitoring system. T2-weighted images (TR=2370ms, TE=41ms, slice thickness=0.7mm, 
FOV=24mmx38mm, 210x320 matrix, pixel size=119µmx119µm) and T1-weighted contrast-
enhanced images prior to and following intravenous administration of 0.1mmolkg-1 gadobutrol 
(Gadovist, Bayer Vital, Leverkusen, Germany) (TR=500ms, TE=9ms, slice thickness=0.7mm, 
FOV=24mmx28mm, 448x512 matrix, pixel size=55µmx55µm) were acquired.  
 
MRI data analysis 
Volumetric analysis was performed using segmentation from regions of interest (ROIs) drawn on 
T2-weighted images. Parameter estimation was undertaken using a Bayesian maximum a posteriori 
algorithm, which took into account the Rician distribution of noise in magnitude MR data in order 
to provide unbiased parameter estimates (27, 28). Estimates of the ADC (x10-6mm2s-1) were 
determined from the EPI-DWI data. DCE MRI data were analysed by incorporating the Tofts and 
Kermode pharmacokinetic model, from which the volume transfer constant (Ktrans, minute−1), the 
rate of flux of contrast agent into the extracellular extravascular space within a given volume, was 
calculated (6).  
All data were fitted on a pixel-by-pixel basis using in-house software (ImageView, developed in 
IDL, ITT Visual Information Systems, Boulder, CO, USA), and the median value of each parameter 
determined from a ROI that encompassed either the whole brain, whole lesion or a portion of the 
lesion.  
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Micro computed tomography 
Intact heads from Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice and wildtype control mice were fixed in 10% 
formalin for at least 48 hours, and patient-derived xenograft-bearing mouse brains were fixed in 4% 
formalin, prior to iodination in Lugol’s iodine (I127 concentration of 2.94x10-4mol/ml) for at least 72 
hours to improve tissue contrast. The heads were then rinsed with distilled water to remove excess 
iodine, blotted dry and secured within a low density plastic container covered with polymer film to 
prevent specimen dehydration. Images were acquired using a Nikon XTH 225 ST µ-CT scanner, 
utilising a molybdenum X-ray source with anode voltages ranging between 70-100 kV and detector 
exposure times of 500-708ms over 3141 projections (2, 14). Data was reconstructed using CTPro3D 
(Nikon Metrology, Tring) and post-processed with VG Studio MAX software (Volume Graphics 
GmbH, Heidelberg, Germany).  
 
Histopathology 
Formalin-fixed Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse tissue imaged by µ-CT was decalcified in 1% 
formic formaldehyde for 48 hours before embedding in paraffin blocks. A further 5 surface 
decalcifications of 2 hours each were performed prior to 5µm sections being cut in the axial or 
sagittal plane, matched to the imaging plane. Sections were then stained with haematoxylin and 
eosin (H&E).  
The brains from patient-derived xenograft-bearing mice were formalin-fixed and processed 
following µCT imaging, and H&E staining of 3µm axial sections was performed as previously 
described (26).  
Slides were scanned using either Nanozoomer (Hamamatsu Photonics, Welwyn Garden City) or 
Pannoramic MIDI (3D-Histech, Sysmex Europe) and processed using CaseViewer 2.0 software 
(3D-Histech, Budapest, Hungary). 
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Statistics 
Statistical and survival analysis was performed with GraphPad Prism 7 (GraphPad Software, La 
Jolla, USA). The mean of median values for quantitative MRI parameters were reported and used 
for statistical analysis. Results are presented as the mean ± 1 standard error of the mean (s.e.m.). 
Significance testing used Student’s unpaired t-test and Pearson correlation coefficient (one tailed) 
with a 5% confidence level.  
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Results 
 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice develop cystic-solid tumours with a non-linear growth pattern 
MRI and µ-CT imaging performed at 8 weeks of age revealed enlargement of the pituitary of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice relative to wildtype control mice (Figure 1A), consistent with the 
previously observed prenatal pituitary hyperplasia (11). Serial T2-weighted MRI performed every 2 
weeks revealed a relatively stable phase with no additional changes detectable, followed by lesion 
enlargement forming a solid tumour with associated cystic fluid accumulation (hyperintense relative 
to midbrain above; Figure 1B) and in most cases haemorrhage (relatively hypointense).  
Tumour progression, defined as a change in imaging phenotype from the stable state, was identified 
in thirteen Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice prior to 1 year of age, at a median age of 17.7 weeks 
(range 8.3 – 35.3 weeks, n=17) (Figure 1C). Median overall survival in the cohort was found to be 
22.6 weeks (range 10.1 – 41.0 weeks). It was noted that tumours that presented later appeared to 
progress more slowly, and indeed the age at which progression was identified correlated 
significantly with the time from progression to sacrifice (Pearson r=0.85, p=0.0002). 
 
Multiparametric MRI reveals radiological features similar to human ACP, which correlate 
with -CT and histology 
Multiparametric MRI was used to assess the phenotype of progressing Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
tumours. Considerable heterogeneity of cystic components, identified by high T2-weighted signal 
intensity, was noted both within and between tumours. In a subset of tumours (n=5) these cysts 
remained hyperintense on FLAIR images, in which the signal from cerebrospinal fluid (CSF) and 
other motile fluid compartments would usually be suppressed, and were also relatively hyperintense 
on T1-weighted images (Figure 2A left panel, arrow). In another subset (n=5) cystic fluid attenuated 
to the same degree as ventricular CSF on FLAIR and was isointense to the midbrain on T1-weighted 
images (Figure 2A, centre panel, arrowhead). Both of these cystic phenotypes were also identified 
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within individual lesions (n=3. Figure 2A right panel) and were consistent with the imaging features 
of the cysts observed in human ACP patients (10).  
 
Quantitative functional MRI incorporating native and contrast-enhanced parameters was also 
performed at study end. Parametric ADC maps demonstrated that whilst the solid tumour 
component appeared to have a similar ADC to the rest of the brain (Figure 2B), there was 
substantial heterogeneity in the tumours corresponding to the different components of the lesions 
(Figure 2B and 2C). Quantification of ADC in eight end-stage tumours that consisted of all three 
tumour components showed that ADC was lowest in the solid component (635±29x10-6mm2s-1), 
was significantly higher in the haemorrhagic component (856±79x10-6mm2s-1, p=0.02) and was 
higher still in the cystic regions (1953±73x10-6mm2s-1, p<0.0001 vs solid and haemorrhagic).  
 
The uptake and distribution of Gd-DTPA contrast agent in the tumours was assessed using two 
techniques. T1-weighted images acquired prior to and following contrast agent administration 
provided qualitative data that showed heterogeneous signal enhancement in the solid tumour 
component but no response in the cystic or haemorrhagic components (Figure 2B). Quantitative 
maps of the transfer coefficient Ktrans (Figure 2C), which here represents a compound biomarker of 
perfusion and permeability, demonstrated heterogeneous distribution in the solid tumour 
component.  
 
Ex vivo µ-CT images of intact tumour-bearing Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse heads, which had 
been imaged in vivo by MRI prior to necropsy, provided higher resolution 3D visualisation of the 
tumours in situ, confirming the complex architecture observed on MRI in addition to more detailed 
evaluation of microcystic components within the solid tumour (Figure 3 and Supplementary videos 
1 and 2). No invasion of the brain parenchyma by the tumour was evident, and whilst smaller cysts 
within the solid tumour mass were preserved, the integrity of the larger cysts was in some cases 
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difficult to assess because tissue shrinkage during fixation separated the tumour from the brain. 
H&E stained sections of the decalcified heads showed clinically relevant histological features 
observed by MRI and µ-CT; for example densely cellular areas of solid tumour, cysts containing 
proteinaceous fluid and/or red blood cells, and cyst walls made up of a simple epithelial layer 
(Figure 3). 
 
Micro-CT imaging of patient-derived ACP xenografts reveals the 3D tumour structure and 
histological features of human ACP 
MRI performed between 124 and 130 days after implantation of uncultured ACP tumour tissue into 
the cerebral hemisphere of nude mice demonstrated successful engraftment, with tumours appearing 
heterogeneous on both T2-weighted and post-contrast T1-weighted images (Figure 4). Ex vivo µ-CT 
of tumour-bearing brains revealed heterogeneous tumours displaying imaging features that 
corresponded to histological features commonly observed in human ACP, such as palisading 
epithelium, epithelial whorls, stellate reticulum, wet keratin and calcification (Figure 4 and 
Supplementary videos 3, 4 and 5). These features were observed to varying degrees in each of the 
xenografts.  
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Discussion 
 
The relevance of preclinical tumour models to human cancer has been a topic of debate for many 
years. Transgenic models, in which expression or knockout of a specific gene in the native tissue of 
origin leads to spontaneously arising tumours, orthotopic xenografts, where cancer cells are 
implanted in the organ from which they originated, and patient-derived xenografts (PDXs), in 
which human tumour tissue is implanted directly from surgical or biopsy samples, are increasingly 
being exploited. The use of these models for preclinical cancer research must be underpinned by 
case-specific evidence for each model establishing that tumour development, progression and 
radiology recapitulates the human disease. In this study we have used longitudinal in vivo MRI and 
high resolution ex vivo μ-CT to compare and contrast the growth patterns and radiological features 
of tumours arising in Hesx1Cre/+;Ctnnb1lox(ex3)/+ transgenic mice and in cerebrally implanted patient-
derived ACP xenografts. 
 
MRI was first performed when Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice were approximately 8 weeks of age, 
where expansion and increased heterogeneity of the pituitary was observed in comparison with 
wildtype control mice. Due to the size of the mouse pituitary (~1mm x 1mm x 3mm) and the 
resolution achievable with in vivo MRI, it was not possible to detect the microscopic structural 
changes previously described, which were observed in utero as early as 9.5 days post coitum (11). 
Micro-CT provided a method for high resolution in situ imaging, achieving resolution of ~9µm3, 
and identified altered architecture of the anterior pituitary and also the posterior lobe of the gland. 
The high radiation exposure required to acquire images at this resolution and tissue contrast 
prohibits the use of this protocol in vivo and thus for longitudinal studies.  
 
Anatomical T2-weighted MRI provides a non-invasive, non-ionising method of monitoring tumour 
growth over extended periods of time. In addition, advanced MRI techniques provide a means of 
14 
 
defining non-invasive quantitative biomarkers to inform on biologically relevant structure-function 
relationships in tumours (5). Serial imaging of Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice revealed that, whilst 
the pituitary was enlarged from early postnatal life, there was indistinguishable growth during a 
stable period prior to progression, in some cases rapid, involving solid tumour growth, cystic 
expansion and other MRI detectable changes. Progressing tumours were identified from 8.3 to 35.3 
weeks old (median 17.7 weeks), with 4/17 animals not demonstrating any imaging changes before 1 
year of age. Overall survival therefore also differed greatly across the cohort with median survival 
being 22.6 weeks (4/17 animals alive beyond 1 year of age), considerably longer than the 
previously reported median survival of 11 weeks, with all animals dying before 6 months of age 
(11). These differences are likely the consequence of variations in the genetic background since the 
original study was performed. The time over which tumours progressed was also variable but we 
show that the age at which tumour progression was identified positively correlated with the time 
from progression to sacrifice; tumours that took longer to progress from the steady state, also 
progressed slower once expansion was identified. The molecular mechanisms underpinning this 
pattern of tumour evolution require further elucidation.  
 
The formation of cysts is a hallmark in the presentation of ACP in children (19) and was observed 
during necropsy in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ model (11). Here, we show that the proportion of 
cystic component varies between tumours, ranging from microcysts within a largely solid lesion, to 
cysts making up approximately 70% of the abnormality. Most interestingly, in approximately half 
of the tumours analysed some or all of these cysts appeared hyperintense on FLAIR images and T1-
weighted images, as is often observed in human ACP (10). This is thought to be caused by the 
presence of high levels of protein, cholesterol and blood breakdown products in the cystic fluid (1, 
10, 12), contributing to its description as ‘engine oil’. Diffusion-weighed MRI showed that the 
ADC of the cystic regions was significantly higher than the other regions of the tumours, 
demonstrating their fluid-filled nature, and ADC values were indistinguishable between cysts that 
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attenuated on FLAIR images and those that remained hyperintense. Diffusion-weighted MRI has 
been investigated, alongside MR spectroscopy, for the evaluation of ACP in the clinic (25). 
Calcification of cyst walls, which is detectable by CT in patients and is integral in the differential 
diagnosis of ACP (29), was not observed in Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours by ex vivo µ-CT, 
which may be related to the relatively short evolution time of mouse tumours compared to human 
tumours.  
 
The solid component of the tumours, which in some cases did not enlarge far beyond the original 
size of the abnormal pituitary, were in themselves heterogeneous with small areas of hypointensity 
on T2-weighted MRI and evidence of microcysts in some cases. These smaller cysts were also 
apparent on μ-CT and histologically, consistent with some human ACPs (22). As expected, these 
regions displayed the most restricted diffusion of water molecules, demonstrating ADC values 
equivalent to those measured in the normal mouse striatum and intracranially implanted murine 
tumours (5, 23). Gadolinium contrast agent extravasation occurred heterogeneously in the solid 
portion of the tumour only, recapitulating the pattern of enhancement in patient tumours (10). In 
patients, some rim enhancement in the cysts occurs; this was not observed preclinically but may be 
a feature of the relatively smaller tumours and relatively lower resolution. Imaging and pathological 
evidence showed that, unlike in patients, the tumours that develop in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice 
do not invade into the brain, which is likely to be as a result of differences in the hypothalamo-
pituitary axis anatomy between mice and humans (18). 
 
The majority of mice (11/13) presented with regions of hypointensity on T2-weighted images, 
which were either hypointense or isointense with the brain parenchyma on T1-weighted images, and 
thus consistent with the presence of paramagnetic species, such as deoxyhaemoglobin, ferritin and 
hemosiderin, from the blood and degradation of erythrocytes associated with haemorrhage. The size 
of these regions varied in size up to approximately 70% of the lesion volume in the most extreme 
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case. ADC in these regions was significantly higher than in the solid component of the tumours but 
was approximately 2.4 fold lower than the fluid in the cysts, suggesting that there are substantial 
barriers to the diffusion of water molecules in these regions. Haemorrhage was also identifiable on 
µ-CT images and H&E staining. The combination of cystic volume and large haemorrhagic regions, 
leading to raised intracranial pressure, was likely the predominant cause of morbidity in the mouse 
cohort. 
 
Patient-derived ACP xenografts also showed MRI features similar to human ACP, consistent with 
the initial description of the model (26). In addition, µ-CT gave further 3D insight into the 
architecture of these tumours, and highlighted several features of human ACP, including 
calcification and specific histological structures such as stellate reticulum, wet keratin and 
palisading epithelium (Figure 4).  
 
As druggable targets are increasingly identified in human and mouse studies (reviewed in (3)) it 
will be important to develop appropriate preclinical strategies to test novel therapeutic agents. The 
two models described here are complementary and recapitulate many of the radiological and 
pathological aspects of human ACP. We anticipate that the use of these murine ACP models will 
improve the accuracy of preclinical data and accelerate the development of urgently required 
targeted therapies for these devastating human tumours.  
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Figure Legends 
 
Figure 1 
A. Axial in vivo T2-weighted MRI (upper panel) and ex vivo micro (µ)-CT (lower panel) images of 
the pituitary region of 8 week old control and Hesx1Cre/+;Ctnnb1lox(ex3)/+ mutant mice (each image 
acquired from a different mouse). Note the expansion and increased heterogeneity of the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (solid arrows) relative to the controls (dashed arrows). 
Arrowheads indicate the posterior lobe of pituitary also detectable in μ-CT images and * denotes 
the sphenoid bone in control mice. MRI resolution 98x98x1000µm; µ-CT resolution approximately 
9µm isotropic. B. T2-weighted MRI images of a Hesx1
Cre/+;Ctnnb1lox(ex3)/+ mouse demonstrating the 
evolution of a tumour. In this mouse the first remarkable change was detected at 17.7 weeks, which 
was followed by rapid tumour progression including growth of the solid component, cyst formation 
and haemorrhage; the mouse was humanely killed at 22.6 weeks according to Home Office 
regulations. C. Progression-free and overall survival curves to 1 year of age representing data from 
seventeen Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice alongside the correlation between time to tumour 
identification and time between identification of tumour and death for twelve animals. Pearson 
correlation coefficient and one tailed significance analysis.  
 
Figure 2 
A. T2-weighted (T2-w), fluid attenuated inversion recovery (FLAIR) and T1-weighted (T1-w) MRI 
images from three Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice demonstrating different cyst imaging 
presentation. Arrows denote cystic fluid that did not attenuate on FLAIR and was hyperintense on 
T1-weighted MRI; arrowheads denote cystic fluid that attenuated on FLAIR and was isointense on 
T1-weighted MRI. The example on the right shows both cyst phenotypes in the same tumour. B. 
Upper panel: T2-weighted and FLAIR images, and a parametric map of apparent diffusion 
coefficient (ADC) acquired from a 1mm thick axial slice through a tumour-bearing 
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Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse head. Lower panel: Matched T1-weighted images acquired at 
baseline and 1 minute after injection of 0.1mmol/kg Gd-DTPA and a subtraction map clearly 
showing areas of signal enhancement. Green ROI denotes lesion volume. C. Parametric maps of 
ADC and transfer coefficient Ktrans in the entire lesion and the solid component of a 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumour alongside a T2-weighted anatomical image of the matched 1mm 
slice. Green ROI denotes solid component of the lesion. Note the heterogeneous signal 
enhancement in the solid tumour components following contrast administration and high ADC in 
cystic areas in B and C. 
 
Figure 3 
In vivo T2-weighted MRI, ex vivo micro (µ)-CT and H&E stained sections from two tumour-bearing 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse heads. Snapshots of H&E staining were acquired at x100 (upper 
panel) and x400 (lower panel) magnification. Arrow denotes densely cellular solid tumour. Small 
cysts contained proteinaceous fluid (+) and/or red blood cells (*). Arrowhead indicates the simple 
epithelial layer that made up the wall of a large cyst. MRI slice thickness 1000µm, μ-CT slice 
thickness ≈ 9µm, tissue sections 5µm.  
 
Figure 4 
In vivo T2-weighted and gadobutrol-enhanced T1-weighted MRI acquired immediately prior to 
necropsy, ex vivo micro (µ)-CT and H&E stained sections from three mice bearing cerebrally-
implanted patient-derived ACP xenografts. Histological features from the patient’s tumour were 
maintained; cell clusters (#) palisading epithelium (arrowhead), stellate reticulum (*), calcification 
(arrows) and wet keratin (+). MRI slice thickness 700µm, μ-CT slice thickness ≈ 4-6µm, tissue 
sections 3µm. 
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Supplementary Material Legends 
 
Supplementary Video 1 
Micro-CT volume rendering (isotropic voxel size=9.1µm) demonstrating virtual dissection of the 
tumour that arose in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse shown in the upper panel of Figure 3. 
Complex areas of cystic and solid tumour can be identified, along with compression of the 
surrounding brain parenchyma.     
 
Supplementary Video 2 
Micro-CT volume rendering (isotropic voxel size=8.7µm) demonstrating virtual dissection of the 
tumour that arose in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse shown in the lower panel of Figure 3. 
Complex areas of cystic and solid tumour can be identified, along with compression of the 
surrounding brain parenchyma.   
 
Supplementary Video 3 
Micro-CT volume rendering (isotropic voxel size=3.7µm) demonstrating virtual dissection of the 
cerebrally-implanted patient-derived ACP xenograft shown in the upper panel of Figure 4. High 
spatial resolution and differential uptake of iodine-based contrast enables visualisation of a cluster 
within an area of stellate reticulum.  
 
Supplementary Video 4 
Micro-CT volume rendering (isotropic voxel size=6.1µm) demonstrating virtual dissection of the 
cerebrally-implanted patient-derived ACP xenograft shown in the middle panel of Figure 4.  A 
radio-dense focus can be seen within the xenograft; this corresponds to an area of calcification on 
histological examination.  
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Supplementary Video 5 
Micro-CT volume rendering (isotropic voxel size=3.8µm) demonstrating virtual dissection of the 
cerebrally-implanted patient-derived ACP xenograft shown in the lower panel of Figure 4. Islands 
of wet keratin adjacent to solid tumour (confirmed on H&E, Figure 4) give the xenograft a 
heterogeneous appearance on micro-CT examination.  
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